Anzeige
Mehr »
Donnerstag, 22.01.2026 - Börsentäglich über 12.000 News
$95 Silber explodiert - Prince Silver vor dem nächsten Durchbruch!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 870747 | ISIN: US5949181045 | Ticker-Symbol: MSF
Tradegate
22.01.26 | 15:34
382,75 Euro
+0,71 % +2,70
1-Jahres-Chart
MICROSOFT CORPORATION Chart 1 Jahr
5-Tage-Chart
MICROSOFT CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
382,90382,9515:35
382,35382,6515:35
ACCESS Newswire
132 Leser
Artikel bewerten:
(0)

Bristol-Myers Squibb Company: Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft's suite of radiology solutions

Originally published on BMS.com

PRINCETON, NJ / ACCESS Newswire / January 22, 2026 / Bristol Myers Squibb (NYSE:BMY, "BMS"), a global leader in oncology, announced an agreement with Microsoft, a market leader in AI-powered radiology and clinical workflow technologies, aiming to accelerate early detection of lung cancer.

Through this digital health collaboration, U.S. FDA-cleared radiology AI algorithms will be deployed via Microsoft's Precision Imaging Network, part of Microsoft for Healthcare radiology solutions. Today, more than 80% of hospitals in the U.S. use Microsoft's award-winning network to share medical imaging and access third-party imaging AI. AI capabilities available through Precision Imaging Network can automatically analyze X-ray and CT images to help identify lung disease, supporting radiologists in their daily workflow and helping reduce clinical workload. These advanced AI algorithms can help surface hard to detect lung nodules, potentially identify patients at earlier stages of lung cancer, and help triage them for appropriate care.

Lung cancer remains the leading cause of cancer-related deaths in the United States, with approximately 125,000 deaths and 227,000 new cases reported annually. Medically underserved populations experience even higher lung cancer mortality rates and are less likely to receive guideline-concordant screening. With more than half of the patients with incidental findings lost to follow-up, the collaboration leverages workflow management tools to track patients with lung nodules through care pathways and help ensure regular follow-up.

"By combining Microsoft's highly scalable radiology solutions with BMS' deep expertise in oncology and drug delivery, we've envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with Non-Small Cell Lung Cancer (NSCLC) and guide them to optimal care pathways and precision therapies," said Dr.Alexandra Goncalves, VP and Head of Digital Health, Bristol Myers Squibb. "An integrated, AI-powered platform that streamlines patient flow can significantly improve operational efficiency and patient outcomes."

A core objective of the collaboration is to expand access to early detection in medically underserved communities, including rural hospitals and community clinics across the United States. By harnessing advanced AI tools, especially in resource-limited settings, this initiative promotes earlier diagnosis and follow-up, enabling more equitable care for all patients.

"This new Microsoft collaboration reflects our commitment to breaking down barriers and addressing healthcare challenges," said Andrew Whitehead, VP and Head of Population Health, Bristol Myers Squibb. "At BMS, health equity is not a standalone initiative-it is embedded in everything we do. By deploying this solution and bringing advanced AI tools to the front lines, together we will help to address health disparities in lung cancer."

The early detection strategy for lung cancer directly supports BMS' commitment to health equity and its focus on scalable, sustainable solutions to improve patient outcomes.

"With Microsoft's AI-powered radiology technology platform widely deployed within healthcare delivery organizations across the country and operating behind the scenes, clinicians can more easily identify patients who may be showing early signs of cancer-often before they are aware of any symptoms-and help guide them into the appropriate care pathway sooner," said Peter Durlach, Corporate Vice President and Chief Strategy Officer, Microsoft Health and Life Sciences. "This is a clear win for both patients and providers and aligns with Microsoft's goals to utilize technology to unlock insights, increase efficiencies, and improve patient care."

View additional multimedia and more ESG storytelling from Bristol-Myers Squibb Company on 3blmedia.com.

Contact Info:
Spokesperson: Bristol-Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com

SOURCE: Bristol-Myers Squibb Company



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bristol-myers-squibb-announces-collaboration-with-microsoft-to-advanc-1129955

© 2026 ACCESS Newswire
Gold & Silber auf Rekordjagd
Kaum eine Entwicklung war 2025 so eindrucksvoll wie der Höhenflug der Edelmetalle. Allen voran Silber: Angetrieben von einem strukturellen Angebotsdefizit, explodierte der Preis und übertrumpfte dabei den „großen Bruder“ Gold. Die Nachfrage aus dem Investmentsektor zieht weiter an, und ein Preisziel von 100 US-Dollar rückt in greifbare Nähe.

Auch Gold markierte neue Meilensteine. Mit dem Durchbruch über 3.000 und 4.000 US-Dollar pro Unze hat sich der übergeordnete Aufwärtstrend eindrucksvoll bestätigt. Rücksetzer bleiben möglich, doch der nächste Zielbereich bei 5.000 US-Dollar ist charttechnisch fest im Blick. Die fundamentalen Treiber sind intakt, eine nachhaltige Trendwende aktuell nicht in Sicht.

Für Anlegerinnen und Anleger bedeutet das: Jetzt ist die Zeit, um gezielt auf starke Produzenten zu setzen. In unserem neuen Spezialreport stellen wir fünf Gold- und Silberaktien vor, die trotz Rallye weiter attraktives Potenzial bieten, mit robusten Fundamentaldaten und starken Projekten in aussichtsreichen Regionen.

Jetzt den kostenlosen Report sichern und von der nächsten Welle im Edelmetall-Boom profitieren!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.